Clovis Oncology, Inc. (NASDAQ:CLVS) Analyst Ratings And Technical Analysis

The stock is lingering around the initial support level of $8.66. After this, the following support is at the zone of $7.88. Up until the time the CLVS stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 48.39 on the daily chart, and this may be a cause for concern. In case the price goes below $7.88 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $10.69 level may cause a pull-back move approaching $11.95 mark.

Clovis Oncology, Inc. (CLVS) is most likely going to rise 68.41 percent in the coming 12 months, as per price target approximations compiled by finviz. Nevertheless, they have set the price target at a $36 as 12-month high price target. This represents a whopping 284.2 percent increase from the current trading price of shares. The 52-week median price target given by the analysts is $9, which means a return possibility of -3.95 percent in comparison with the closing price of the stock of $9.37 in recent trading session. The lowest price set for the stock is $3 which is just above -67.98 percent from CLVS share’s price at the end of session.

Let’s take a glimpse at some insider activity at Clovis Oncology, Inc. (NASDAQ:CLVS) and observe the pattern. The earliest insider trade happened on 12/20/2019. Rolfe Lindsey parted with a total of 1.73 thousand shares of the firm at average share price of $11.3. The total amount for the sale was set at $19.54 thousand. On completing this exchange, the insider’s account balance was 26.23 thousand shares. The stock lost -6.64 percent from that insider sale. On 12/20/2019, IVERS-READ GILLIAN C, did a sale of 0.83 thousand shares at a price of $11.3 per share. This got rid of 9.38 thousand shares from the insider’s fortune and the stock experienced a -6.64 percent retreat in price since the news became public. This exchange saw 195.27 thousand shares get out from the insider’s account. On 12/03/2019, Rolfe Lindsey recorded a sale transaction valued at $9.84 thousand. The sale at $14.6 a share has eliminated 0.67 thousand shares from the insider’s portfolio position. Meanwhile, shares price witnessed -27.74 percent decrease since the transaction reporting date. The company insider is left with 24.52 thousand shares remaining in the account. MUEHL DANIEL W, performed a sale of 0.47 thousand shares in a transaction worth $6.8 thousand. The disposal recorded on 12/03/2019 was priced at $14.59 per share. The stock price plunged -27.69 percent since the transaction. MUEHL DANIEL W currently holds a stake of 9.93 thousand in CLVS stock which is worth $93.08 thousand after the insider selling.

In the recent trading session, Clovis Oncology, Inc. (NASDAQ:CLVS) shares lost -0.64% or -0.06 points to reach at $9.37 with a thin trading volume of 2.382 million shares. It opened the trading session at $10.85, the shares rose to $11.18 and dropped to $9.145, the range by which the price of stock traded the whole session. The company now has a market cap of $561 million and currently has 59.53 million outstanding shares. Clovis Oncology, Inc. (CLVS) stock has plunged -26.67 percent of market value in 21 trading days.

Stock analysts at H.C. Wainwright lifted target price for Clovis Oncology, Inc. (NASDAQ:CLVS) shares but reaffirmed their Buy recommendation for the stock in their opinion released on January 08. The price target has been increased from $36 to $27. Evercore ISI analysts have downgraded their rating of CLVS shares from Outperform to In-line in a separate flash note to investors on November 19. Analysts at SVB Leerink downgraded the company stock to a Mkt Perform call from its previous Outperform stance, in a flash note that dated back to September 24.

CLVS stock’s trailing 3-year beta is 3.22, meaning there will be a greater rate of return, although posing a higher risk. The part of a firm’s profit given to each outstanding share of regular stock was -$7.51 share in the trailing 52 weeks. The stock’s value fallen -9.54 percent year to date (YTD) compared to a decline of -59.55 percent in 52 week’s period. The firm’s shares are still trading -70.76 percent below its 1-year high of $32.05 and 219.8 percent up from 52-week low of $2.93. The average consensus ranking on the company is 2.7, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a sell.

Clovis Oncology, Inc. (CLVS) shares are trading at a P/E ratio of -1.23 times earnings posted in the trailing 12 months. The industry CLVS deals with has an average P/E of 25.19. Its P/B ratio is standing at -3.23X compared to the 11.59 industry average. It is additionally sporting a 1.61 on the Price-to-Sales ratio, compared to the industry’s P/S average of 2.83. Clovis Oncology, Inc. has a 79% gross profit margin.

Past records have indicated that shares in Clovis Oncology, Inc. declined on 17 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings. Investors will get the next hint of CLVS’s Q4 earnings on February 25. Analysts are predicting revenue to climb 29.6 percent to $39.32M in the financial fourth quarter, while EPS will soar by about -6.91 percent to -$1.75 per share. In the last quarter, it’s earnings of -$1.72 per share came better than the -$1.72461, adjusted, expected by Thomson Reuters consensus estimate. Revenue for the quarter was $30.35M, missing the $30.46M analysts had expected. Earnings are seen to rise by -80.5 percent this year, 32.5 percent in the coming year and the trend continues by 35.1 percent every year in the next 5 years.